Investment analysts at JPMorgan Chase & Co. began coverage on shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in a research note issued on Thursday. The brokerage set an “overweight” rating on the stock.

Several other analysts also recently commented on TMO. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $175.00 price objective on the stock in a report on Wednesday, July 20th. BTIG Research upgraded shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and set a $180.00 target price for the company in a research note on Friday, July 22nd. Mizuho set a $175.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, July 28th. Cleveland Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Friday, September 9th. Finally, Jefferies Group reiterated a “hold” rating on shares of Thermo Fisher Scientific in a research note on Thursday, August 4th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $159.66.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific (NYSE:TMO) opened at 155.42 on Thursday. Thermo Fisher Scientific has a 1-year low of $117.10 and a 1-year high of $160.68. The company’s 50-day moving average is $152.61 and its 200 day moving average is $149.02. The stock has a market capitalization of $61.28 billion, a PE ratio of 31.09 and a beta of 1.00.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/jpmorgan-chase-co-begins-coverage-on-thermo-fisher-scientific-inc-tmo.html

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 28th. The company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.02. The company had revenue of $4.54 billion for the quarter, compared to the consensus estimate of $4.50 billion. Thermo Fisher Scientific had a net margin of 11.35% and a return on equity of 14.70%. Thermo Fisher Scientific’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.84 EPS. Equities analysts predict that Thermo Fisher Scientific will post $8.16 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Monday, October 17th. Shareholders of record on Thursday, September 15th will be paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.39%. The ex-dividend date is Tuesday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 12.02%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 20,000 shares of the stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $147.69, for a total transaction of $2,953,800.00. Following the completion of the transaction, the chief executive officer now owns 340,998 shares of the company’s stock, valued at $50,361,994.62. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 30,000 shares of the stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $148.85, for a total transaction of $4,465,500.00. Following the transaction, the chief executive officer now directly owns 350,998 shares of the company’s stock, valued at approximately $52,246,052.30. The disclosure for this sale can be found here. Company insiders own 0.52% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in TMO. Emerald Acquisition Ltd. bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at $200,618,000. Wellington Management Group LLP raised its position in shares of Thermo Fisher Scientific by 26.0% in the first quarter. Wellington Management Group LLP now owns 6,135,669 shares of the company’s stock valued at $868,749,000 after buying an additional 1,267,967 shares during the period. Sound Shore Management Inc. CT raised its position in shares of Thermo Fisher Scientific by 123.5% in the second quarter. Sound Shore Management Inc. CT now owns 2,204,253 shares of the company’s stock valued at $138,096,000 after buying an additional 1,217,950 shares during the period. FMR LLC raised its position in shares of Thermo Fisher Scientific by 11.3% in the second quarter. FMR LLC now owns 8,216,645 shares of the company’s stock valued at $1,214,093,000 after buying an additional 834,858 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Thermo Fisher Scientific by 72.3% in the first quarter. JPMorgan Chase & Co. now owns 1,953,935 shares of the company’s stock valued at $276,658,000 after buying an additional 820,110 shares during the period. 87.38% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.